Pathophysiology of cisplatin-induced acute kidney injury.
Ozkok A, Edelstein CL. · 2014
Read Pathophysiology of cisplatin-induced acute kidney injury. by Ozkok A, Edelstein CL. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4140112.txt.
Introduction
Abdullah Ozkok and Charles L. Edelstein reviewed how the cancer drug cisplatin injures the kidneys. Their review appeared in BioMed Research International in 2014. Cisplatin and its relatives are mainstays against solid tumours, but acute kidney injury is a known complication that often forces dose cuts or withdrawal.
The harm is cumulative and dose-dependent, and repeated episodes can end in chronic kidney disease. Inside the kidney, the drug damages the proximal tubules through outright cell death and programmed death, with oxidative stress, inflammation, and vessel injury alongside. Blocking single inflammatory signals, or removing certain immune cells, protects animals from the injury. Understanding the mechanism, the authors argue, is the route to add-on therapies that spare the kidney.
Catalog record
| CREATOR | Ozkok A, Edelstein CL. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 86 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Pathophysiology of Cisplatin-Induced Acute Kidney Injury By Abdullah Ozkok, Charles L. Edelstein Published in: BioMed Research International DOI: 10.1155/2014/967826 ABSTRACT Cisplatin and other platinum derivatives are the most widely used chemotherapeutic agents to treat solid tumors including ovarian, head and neck, and testicular germ cell tumors. A known complication of cisplatin administration is acute kidney injury (AKI). The nephrotoxic effect of cisplatin is cumulative and dose-dependent and often necessitates dose reduction or withdrawal. Recurrent episodes of AKI may result in chronic kidney disease. The pathophysiology of cisplatin-induced AKI involves proximal tubular injury, oxidative stress, inflammation, and vascular injury in the kidney. There is predominantly acute tubular necrosis and also apoptosis in the proximal tubules. There is activation of multiple proinflammatory cytokines and infiltration of inflammatory cells in the kidney. Inhibition of the proinflammatory cytokines TNF-α or IL-33 or depletion of CD4+ T cells or mast cells protects against cisplatin-induced AKI. Cisplatin also causes endothelial cell injury. An understanding of the pathogenesis of cisplatin-induced AKI is important for the development of adjunctive therapies to prevent AKI, to lessen the need for dose decrease or drug withdrawal, and to lessen patient morbidity and mortality. 1. INTRODUCTION Acute kidney injury (AKI) is defined as a clinical syndrome characterized by a rapid decrease in renal function together with the accumulation of waste products such as urea [1]. The incidence of non-dialysis-requiring AKI is about 5000 cases per million people per year and incidence of dialysis requiring AKI is 295 cases per million people per year [2]. AKI complicates 1–7% of all hospital admissions and 1–25% of intensive care unit admissions [3, 4]. Furthermore, AKI is known as an independent risk factor for mortality. AKI increases the risk of death by 10- to 15-fold and results in a mortality rate of 50% [5, 6]. The kidneys are the major targets for the toxic effects of various chemical agents and thus drug-induced AKI is a frequent entity in clinical medicine. The incidence of nephrotoxic AKI is difficult to estimate due to variabilities of patient populations and criteria of AKI. However, nephrotoxicity has been reported to contribute to about 8–60% of hospital-acquired AKI cases [7]. In a recent large multicenter epidemiological survey performed on critically ill patients, drug nephrotoxicity was found to be responsible for 19% of AKI cases [8]. Cisplatin (dichlorodiamino platinum) is an inorganic platinum-based chemotherapeutic agent that is widely used in the treatment of a variety of solid malignant tumors such as head and neck, lung, testis, ovarian, and bladder cancers [9]. The use of cisplatin is frequently limited by various significant side effects such as bone marrow suppression, peripheral neuropathy, ototoxicity, anaphylaxis, and nephrotoxicity. After a single dose of cisplatin (50–100 mg/m2), approximately one-third of the patients develop nephrotoxicity [10, 11]. An improved knowledge of the pathogenesis of cisplatin-induced AKI is crucial to prevent the AKI and improve survival in cancer patients receiving cisplatin-based treatments. Furthermore, increased renal vascular resistance and decreases in renal plasma flow and glomerular filtration rate (GFR) make the cisplatin nephrotoxicity an ideal model to study the early pathophysiological features of all types of AKI [12]. In this paper, we aim to review the pathophysiological mechanisms of cisplatin-induced AKI and discuss the most recent experimental strategies and molecules to prevent cisplatin-induced AKI. 2. CELLULAR UPTAKE OF CISPLATIN Uptake of the cisplatin by the renal cells is energy dependent and can be inhibited by probenecid [13]. Deletion of the Ctr1, a high-affinity copper transporter, results in reduced uptake of cisplatin and toxicity in yeast [14]. Ctr1 knockdown significantly reduced cisplatin-induced apoptosis in renal proximal tubular cells (RPTC) [15]. Organic cation transporters (OCTs) also play a role in cellular uptake of cisplatin [16]. Cimetidine, an OCT2 inhibitor, decreases cisplatin uptake in cultured renal tubular cells [17]. Cisplatin uptake and toxicity were shown to be increased in OCT2 overexpressing human proximal tubular cells [17]. However, OCT1/OCT2-deficient mice were protected from cisplatin-induced renal tubular damage [18, 19]. Cisplatin becomes highly reactive within the cell. Cisplatin conjugates with molecules such as glutathione, proteins, RNA, and DNA. Intra- and interstrand cross-linking of DNA by cisplatin block DNA replication and gene transcription. Thus, DNA damage is a critical component of cisplatin toxicity [20, 21]. Due to its low molecular weight and uncharged character, unbound cisplatin in the plasma is freely filtered by the glomerulus. Most of the cisplatin is trapped within the renal cortex [13, 22]. The concentration of cisplatin in the proximal tubular cells is 5 times higher than the serum concentration and thus such an accumulation of cisplatin in kidney contributes to its nephrotoxicity [9, 23]. 3. GENERAL PATHOPHYSIOLOGY The pathophysiology of cisplatin-induced AKI involves 4 major mechanisms: (1) proximal tubular injury, (2) oxidative stress, (3) inflammation, and (4) vascular injury in the kidney. Proximal tubular injury involves several different mechanisms including apoptosis [24], autophagy [25], dysregulation of cell-cycle proteins [26], activation of the mitogen-activated protein kinase (MAPK) signaling pathways [27], direct toxicity to renal tubular epithelial cells [17], DNA damage [28], and mitochondrial dysfunction [29]. 4. PROXIMAL TUBULAR INJURY 4.1. Apoptosis The dosage of cisplatin determines whether the cells die by necrosis or apoptosis [30]. In cell culture studies, high concentrations of cisplatin cause necrotic cell death but lower concentrations lead to apoptosis. However, in vivo, cisplatin induces both necrosis and apoptosis [31]. Several pathways are defined for apoptosis such as the extrinsic pathway induced by death receptors, the intrinsic pathway depending mostly on mitochondria, and the endoplasmic reticulum (ER) stress pathway. In the extrinsic pathway, activation of death receptors such as Fas and tumor necrosis factor-alpha (TNFR) leads to activation of downstream caspases to induce apoptosis [32]. In the intrinsic pathway, cellular injury leads to the activation of the proapoptotic Bax and Bak proteins, which in turn results in the release of apoptogenic factors including cytochrome c, apoptosis-inducing factor (AIF), Smac/DIABLO, and endonuclease G from the mitochondria. Cisplatin induces Bax activation [33] and inhibition of Bax by Bcl-2 diminishes mitochondrial injury and cisplatin-induced apoptosis [34]. Importantly, when the Bax gene was deleted, the animals became resistant to cisplatin [24]. In the ER stress pathway of apoptosis, the initiator caspase is caspase-12 which was shown to be activated by cisplatin. In a cell culture study, apoptosis was found to be attenuated with transfection of an anti-caspase-12 antibody [35]. Another ER-associated protein during cisplatin injury is a calcium-independent phospholipase A2 (ER-iPLA2). Inhibition of ER-iPLA2 leads to amelioration of cisplatin-induced apoptosis in proximal tubular cultures [36]. In addition to caspases and proapoptotic pathways, there are other pathways like p53 that are activated in cisplatin-induced AKI. 4.1.1. p53 and Apoptosis In cultured renal tubular cells, p53 was shown to be activated by cisplatin [37]. Cisplatin induces DNA damage and subsequently DNA damage response proteins such as ataxia telangiectasia-mutated (ATM) proteins are activated leading to p53 phosphorylation. It was shown that both genetic and pharmacological inhibition (pifithrin) of p53 decreased the tubular cell apoptosis, renal tissue damage, and cisplatin-induced AKI [38]. Several p53-associated pathways and molecules have been defined such as p53 upregulated modulator of apoptosis (PUMA), histone deacetylase (HDAC) inhibitors, taurine transporter gene (TauT), and SIRT1 which are all implicated in the pathophysiology of cisplatin-induced AKI. PUMA, a proapoptotic protein, was identified as a major downstream